Some papers arrive wearing a lab coat. This one shows up carrying a tiny molecular bouncer and says, "No cross-correction, nobody gets in." The researchers wanted to answer an annoying question in Sanfilippo B syndrome: when heparan sulfate drops in cerebrospinal fluid, does that really mean the brain is improving, or is the body just throwing biochemical glitter everywhere?

The Brain Problem With a Very Long Name

Sanfilippo syndrome type B, also called MPS IIIB, is a rare inherited disorder caused by loss of the enzyme NAGLU. Without it, cells cannot properly break down heparan sulfate, a sugar-rich molecule involved in cell signaling. In Sanfilippo, that material piles up inside lysosomes, the cell's recycling centers when they are not acting like overstuffed junk drawers. The result is progressive brain disease in children, with developmental decline, behavior changes, sleep problems, and loss of function over time (GeneReviews; Sanfilippo syndrome, Wikipedia; Heparan sulfate, Wikipedia).

That brings us to cerebrospinal fluid, or CSF, the liquid bathing the brain and spinal cord. If you can measure something there that reliably tracks brain disease, you have a biomarker clinicians can actually use.

The Clever Mouse Hack

The new study from Le and colleagues did not just treat mice and call it a day. They engineered a version of NAGLU that stays stuck to the cell membrane by fusing it to part of LAMP1. Translation: the enzyme could work inside the treated cell, but it could not easily leak out and rescue neighboring cells from a distance. That let the team separate local brain correction from the usual lysosomal-therapy magic trick called cross-correction (Le et al., 2025).

Then they ran two experiments in Sanfilippo B mice.

First, they gave the membrane-tethered enzyme through the bloodstream using a viral vector that does not cross the blood-brain barrier. That lowered heparan sulfate in the blood, but not in the brain and not in CSF.

Second, they delivered the same general strategy directly into the brain's ventricular system, using a neuron-focused promoter. This time brain heparan sulfate normalized, CSF heparan sulfate fell, and markers of neuroinflammation improved. Blood levels did not budge in a meaningful way.

That is the punch line: in this model, CSF heparan sulfate tracked brain correction, not peripheral cleanup. The marker was not being fooled by body-wide biochemical housekeeping.

Why People in This Field Care So Much

This may sound like a niche argument about sugar fragments in spinal fluid, but it lands in a very real bottleneck in rare-disease drug development. For neuronopathic mucopolysaccharidoses, waiting years for cognitive outcomes in tiny patient populations is brutally hard. A 2024 community consensus paper argued that CSF heparan sulfate can support accelerated approval decisions because it is tied closely to the disease process itself (Muenzer et al., 2024).

And this is not happening in a vacuum. In a phase I/II clinical study of intracerebroventricular tralesinidase alfa for Sanfilippo B, investigators reported normalization of CSF heparan sulfate and heparan sulfate nonreducing ends at the higher dose, alongside signals consistent with slowed disease progression (Muschol et al., 2022). In July 2024, advocacy groups highlighted the push to use CSF heparan sulfate as a surrogate endpoint, and by May 1, 2025, international organizations were publicly calling for formal recognition of it as a primary disease activity biomarker in neuronopathic MPS (Sanfilippo Australia, July 22, 2024; IMPSN/MPS Society UK statement, May 1, 2025).

So this mouse paper is doing more than it first appears. It is stress-testing the logic behind a biomarker that could speed up how therapies are judged in children with a devastating neurodegenerative disorder. Not bad for a paper whose central move was basically "what if we glued the enzyme down and made it stop being helpful?"

The Catch, Because There Is Always a Catch

It is still a mouse study. Mice are excellent for mechanism and terrible at filling out quality-of-life surveys. CSF biomarkers are powerful, but they are still proxies. Families care about cognition, communication, sleep, mobility, and whether life stops feeling like an endless alarm bell at 3 a.m.

There is also a bigger biology story here. Sanfilippo damage is not just storage. Recent work points to white matter injury and neuroinflammatory signaling as part of the mess, which helps explain why clearing substrate may not be the whole symphony, just the bass line that keeps everything from collapsing (Taherzadeh et al., 2023; Dias et al., 2024).

Still, this is the kind of study that makes a field less hand-wavy. It turns a plausible biomarker into a more believable one. And in rare pediatric brain disease, believable can be the difference between "maybe someday" and a trial that actually moves.

References

Le SQ, Sorensen A, Sukupolvi S, et al. Reduced heparan sulfate levels in cerebrospinal fluid reflect brain neuron correction in Sanfilippo B mice. J Clin Invest. 2025;135(22):e195268. DOI: https://doi.org/10.1172/JCI195268

Muenzer J, Ho C, Lau H, et al. Community consensus for heparan sulfate as a biomarker to support accelerated approval in neuronopathic mucopolysaccharidoses. Mol Genet Metab. 2024;142(4):108535. PMID: https://pubmed.ncbi.nlm.nih.gov/39018614/

Muschol N, Koehn A, von Cossel K, et al. A phase I/II study on intracerebroventricular tralesinidase alfa in patients with Sanfilippo syndrome type B. J Clin Invest. 2023;133(2):e165076. DOI: https://doi.org/10.1172/JCI165076

Taherzadeh M, Zhang E, Londono I, et al. Severe central nervous system demyelination in Sanfilippo disease. Front Mol Neurosci. 2023;16:1323449. DOI: https://doi.org/10.3389/fnmol.2023.1323449

Dias C, Ballout N, Morla G, et al. Extracellular vesicles from microglial cells activated by abnormal heparan sulfate oligosaccharides from Sanfilippo patients impair neuronal dendritic arborization. Mol Med. 2024;30:197. DOI: https://doi.org/10.1186/s10020-024-00953-1

Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.